Wedbush reaffirmed their hold rating on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research report report published on Thursday, AnalystRatings.com reports. The firm currently has a $1.00 target price on the biopharmaceutical company’s stock. Wedbush also issued estimates for Regulus Therapeutics’ Q2 2019 earnings at ($0.19) EPS, Q3 2019 earnings at ($0.27) EPS, Q4 2019 earnings at ($0.25) EPS, FY2019 earnings at ($1.41) EPS, Q1 2020 earnings at ($0.26) EPS, Q2 2020 earnings at ($0.27) EPS, Q3 2020 earnings at ($0.28) EPS, Q4 2020 earnings at ($0.29) EPS and FY2020 earnings at ($1.09) EPS.
Other equities research analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Regulus Therapeutics from a hold rating to a buy rating and set a $1.25 price target on the stock in a research note on Friday, March 29th. Wells Fargo & Co decreased their price target on shares of Regulus Therapeutics from $6.00 to $1.50 and set a market perform rating on the stock in a research note on Tuesday, March 19th. Finally, ValuEngine downgraded shares of Regulus Therapeutics from a hold rating to a sell rating in a research note on Wednesday, May 1st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and an average target price of $1.06.
Shares of NASDAQ:RGLS opened at $1.16 on Thursday. Regulus Therapeutics has a fifty-two week low of $0.80 and a fifty-two week high of $9.48. The firm has a market cap of $23.84 million, a P/E ratio of -0.21 and a beta of 2.26.
In other news, CEO Joseph P. Hagan bought 33,194 shares of Regulus Therapeutics stock in a transaction dated Tuesday, May 7th. The shares were acquired at an average price of $1.08 per share, with a total value of $35,849.52. Following the completion of the purchase, the chief executive officer now owns 64,542 shares in the company, valued at approximately $69,705.36. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Pascale Witz bought 29,630 shares of Regulus Therapeutics stock in a transaction dated Tuesday, May 7th. The stock was purchased at an average cost of $1.08 per share, for a total transaction of $32,000.40. Following the purchase, the director now owns 37,849 shares of the company’s stock, valued at approximately $40,876.92. The disclosure for this purchase can be found here. In the last three months, insiders bought 1,199,528 shares of company stock worth $1,295,490 and sold 68,107 shares worth $83,478. Corporate insiders own 5.40% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in RGLS. Renaissance Technologies LLC grew its position in shares of Regulus Therapeutics by 396.3% during the 3rd quarter. Renaissance Technologies LLC now owns 595,501 shares of the biopharmaceutical company’s stock valued at $118,000 after acquiring an additional 475,512 shares during the period. Virtu Financial LLC bought a new position in shares of Regulus Therapeutics during the 1st quarter valued at approximately $68,000. Wedbush Securities Inc. grew its position in shares of Regulus Therapeutics by 32.8% during the 1st quarter. Wedbush Securities Inc. now owns 43,489 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 10,751 shares during the period. Finally, Jane Street Group LLC bought a new position in shares of Regulus Therapeutics during the 1st quarter valued at approximately $64,000. 25.17% of the stock is currently owned by institutional investors and hedge funds.
About Regulus Therapeutics
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Featured Story: Bar Chart
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.